GS24-B039 / GeneScience - LARVOL DELTA

Preclinical pharmacokinetic and pharmacodynamic study of GS24-B039, a 3-month long-acting abiraterone prodrug (ESMO 2025) - "The exposure of abiraterone after a single IM injection of GS24-B039 was 2.96-fold higher than that of AD (PRL-02, the first long-acting abiraterone prodrug in clinical trials) in the same vehicle. Legal entity responsible for the study Changchun GeneScience Pharmaceutical Co., Ltd. Funding Changchun GeneScience Pharmaceutical Co., Ltd."

PK/PD data • Preclinical • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor